Vertex: A Cystic Fibrosis Institution with a Bright Future

Yesterday, Wednesday July 19, Vertex’s (VRTX) stock added over 20% to its value, recording a new all time high. Why?

On Tuesday the firm announced a better than technical analysts’ and its own expectations’ results in three trials testing its cystic fibrosis (CF) drugs VX-152, VX-440 and VX-659 combined with two the its cystic fibrosis drugs. The positive data came from Phase 1 and Phase 2 studies of three different triple combination regimens in cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.